

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Veenstra

Appl. No.: 10/527,518

Filed: 26 September 2005

For: **Aroyl-Piperidine Derivatives**

Confirmation No.: 3808

Art Unit: 1625

Examiner: Seaman, D. Margaret M.

Atty. Docket: PN/4-32655A  
(62106.00004)

**Mail Stop RCE**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**Request for Continued Examination Pursuant to 37 C.F.R § 1.114 and  
Information Disclosure Statement Pursuant to 37 CFR § 1.97(b)(4)**

Dear Sir:

Applicant hereby submits this Request for Continued Examination pursuant to 37 C.F.R. § 1.114, including applicable fee, along with an Information Disclosure Statement pursuant to 37 C.F.R. § 1.97(b)(4).

This Information Disclosure Statement is being filed by Applicant prior to the mailing of a first Office Action after the filing of a Request for Continued Examination. Therefore, no fee or certification is required in connection with this Disclosure.

In accordance with 37 C.F.R. § 1.56, Applicant wishes to call the Examiner's attention to the references cited on the attached form PTO-1449. The U.S. patent reference and Chinese literature were cited in a Chinese Office Action in a counterpart foreign application during July 2006. Copies of the references, with the exception of any U.S. patents, are enclosed herewith.

It is respectfully requested that the information be considered by the Examiner and that a copy of the attached Form PTO-1449 be returned indicating that such information has been considered.

In the event any fees are required in connection with this paper, the USPTO is authorized to charge Deposit Account No. 50-4764

Respectfully submitted,  
**Montgomery, McCracken, Walker & Rhoads, LLP**



Kristin Mazany Nevins  
Registration No. 56,775  
Attorney for Applicant

Date: April 15, 2009  
123 S. Broad Street  
Philadelphia, PA 19109  
215-772-7655